Maintaining glycemic control and managing blood pressure (through inhibition of the renin-angiotensin-aldosterone system) remain fundamental in managing DKD, with added emphasis on nephroprotective medication choices that target glycemic control, hypertension, lipid abnormalities, proteinuria, uric acid management, addressing edema, anemia, and other associated conditions [39]. The gene discussed is REN; the disease is anemia (phenotype).